HKHing Cheong Kok

Hing Cheong Kok

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hing Cheong Kok has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Siew Moy Fong

    Department of Paediatrics, Sabah Women and Children’s Hospital, Kota Kinabalu, Malaysia

    6 shared publications
  • Ian Brent Masters

    Australian Centre for Health Services Innovation and School of Medicine, Queensland University of Technology, Brisbane, Queensland, Australia

    3 shared publications
  • Keith Grimwood

    Child and Maternal Health Division, Menzies School of Health Research Charles Darwin University Darwin NT Australia

    3 shared publications
  • Anne B Chang

    Child and Maternal Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia

    2 shared publications
  • Anne Bernadette Chang

    Charles Darwin University Darwin Northern Territory Australia

    2 shared publications
  • Bilawara Lee

    Child and Maternal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia

    2 shared publications

Latest Publications

  • Development of a paediatric severity score to predict outcomes of radiographic-confirmed community-acquired pneumonia in hospitalised children in Sabah, Malaysia

    by Hing Cheong Kok, Siew Moy Fong, Stephanie T Yerkovich, Keith Grimwood, Ian Brent Masters, Gabrielle B McCallum, Nicholas Fancourt, Chai Woon Gan, Qing Yu Tan, Ethan M Moore, et al.

    Objective: Risk prediction models for community-acquired pneumonia (CAP) in hospitalised children are limited, especially in upper-middle-income countries. We developed a PaEdiatric Pneumonia Severity (PEPS) score to aid early risk stratification and examined its discriminatory ability. Design: Prospective cohort study. Settings and patients: Between April 2022 and April 2023, children aged 1 month to adj )=6.81, 95% CI 4.65 to 9.98), partial/unvaccinated status (OR adj =2.66, 95% CI 1.47 to 4.81), vomiting/refusal of feeds (OR adj =1.77, 95% CI 1.19 to 2.61), hypoxaemia (oxygen saturation 90–93% (OR adj =2.38, 95% CI 1.22 to 4.64); adj =28.88, 95% CI 13.37 to 62.35)) and anaemia (OR adj =1.76, 95% CI 1.17 to 2.67). The model demonstrated excellent discrimination in identifying risk of children having moderate/severe CAP (c-statistic=0.81, 95% CI 0.78 to 0.84). The developed PEPS score (0–13) stratified children into low-risk (score 0–1), moderate-risk (score 2–4) and high-risk (score ≥5) groups with observed rates of moderate/severe CAP 10.9%, 29.1%, and 76.9%, respectively, and demonstrated strong predictive performance for moderate/severe CAP (c-statistic=0.81, 95% CI 0.77 to 0.84). Conclusion: The PEPS score, the first developed in an upper-middle-income country using radiographic-confirmed CAP, accurately discriminates mild from moderate/severe hospitalised CAP. It may support case management in similar settings, but requires external validation before broader implementation.


  • Factors Associated With In‐Hospital and Postdischarge Adverse Outcomes Among Children Hospitalized With Community‐Acquired Pneumonia in Sabah, Malaysia: A Prospective Cohort Study

    by Hing Cheong Kok, Siew Moy Fong, Stephanie T. Yerkovich, Keith Grimwood, Ian Brent Masters, Gabrielle B. McCallum, Nicholas Fancourt, Chai Woon Gan, Qing Yu Tan, Ethan M. Moore, et al.

    Introduction: Adverse in‐hospital outcomes of childhood pneumonia are well‐documented, but adverse postdischarge outcomes remain unclear, especially in middle‐income countries. We investigated factors associated with in‐hospital and postdischarge adverse outcomes in Malaysian children with pneumonia. Methods: Between April 2022 and April 2023, a prospective cohort of Malaysian children aged 1 month to < 12 years hospitalized with radiographic‐confirmed pneumonia were enrolled and reviewed 4–6 weeks postdischarge. Composite in‐hospital adverse outcomes were death, intensive care admission, or prolonged hospitalization > 5 days. Composite postdischarge adverse outcomes were chronic (> 4 weeks) wet cough, rehospitalization for acute lower respiratory infection (ALRI), or unscheduled respiratory‐related doctor visit by 4–6 weeks. Results: In 868 children, composite in‐hospital adverse outcomes occurred in 139 (16%) (2 deaths [< 1%], 46 [5%] intensive care admissions, 136 [16%] prolonged hospitalizations). Risk factors for in‐hospital adverse outcomes were: age < 6 months (adjusted odds ratio [OR adj ] = 3.84, 95% confidence interval [CI] 2.13–6.93), preterm birth (OR adj  = 1.81, 95% CI 1.01–3.23), partial/unvaccinated status (OR adj  = 2.28, 95% CI 1.13–4.60), hypoxemia (OR adj  = 4.91, 95% CI 2.95–8.20), airspace abnormalities (OR adj  = 9.80, 95% CI 3.84–24.98), and anemia (OR adj  = 1.70, 95% CI 1.08–2.68). Among 689/866 (80%) children reviewed postdischarge, 666 (97%) had complete data. Of these, composite postdischarge outcomes occurred in 134 (20%) children (20 [3%] chronic wet cough, 71 [11%] hospitalized ALRIs, 128 [19%] unscheduled respiratory‐related doctor visits). Preterm birth (OR adj  = 2.28, 95% CI 1.37–3.81) and invasive mechanical ventilation (OR adj  = 2.64, 95% CI 1.16–6.00) were risk factors for postdischarge adverse outcomes. Conclusions: Children hospitalized with radiographic‐confirmed pneumonia and at risk of in‐hospital adverse outcomes should be monitored closely. Postdischarge follow‐up is recommended for preterm children or those requiring invasive mechanical ventilation because of their risk of long‐term respiratory morbidity.


  • Association between hospitalised childhood pneumonia and follow-up chest radiographs in high-risk populations: a secondary analysis of a multicentre randomised controlled trial

    by Hing Cheong Kok, Stephanie T Yerkovich, Gabrielle B McCallum, Keith Grimwood, Ian Brent Masters, Nicholas Fancourt, Siew Moy Fong, Anna M Nathan, Catherine A Byrnes, Robert S Ware, et al.

    Objective: As children hospitalised with community-acquired pneumonia (CAP) are at risk of persistent chest radiograph (CXR) abnormalities and respiratory sequelae, we investigated factors associated with incomplete CXR resolution at 4 weeks and 12 months post-discharge in children from populations at high-risk of chronic lung disease.Design: Secondary analysis−multicentre, placebo-controlled, randomised controlled trial.Settings and patients: 324 children aged 3 months to ≤5 years hospitalised with radiographic-confirmed CAP were enrolled from seven hospitals in Australia, New Zealand and Malaysia. After 1–3 days of intravenous antibiotics, then 3 days of oral amoxicillin–clavulanate, they were randomised to extended (13–14 days) or standard (5–6 days) courses of antibiotics.Intervention: CXRs were performed at admission, 4 weeks, and 12 months post-discharge and reviewed in a blinded manner.Main outcome measures: Radiographic changes of pneumonia at 4 weeks and 12 months post-discharge compared with admission CXRs.Results: Among children with interpretable CXRs, incomplete resolution was seen in 42/253 (17%) at 4 weeks, and 29/212 (14%) at 12 months. Characteristics at admission associated with incomplete CXR resolution at 4 weeks were previous pneumonia hospitalisation (adjusted odds ratio [ORadj])=6.46, 95% confidence interval [CI] 2.21 to 18.85) and increasing age (ORadj=0.60 per-year, 95% CI 0.38 to 0.94). Continuing respiratory symptoms/signs at 4 weeks post-discharge was also associated with incomplete resolution (OR=5.63, 95% CI 2.38 to 13.32). At 12 months, previous pneumonia hospitalisation was associated with persistent incomplete CXR resolution (OR=4.03, 95 % CI 1.25 to 13.02).Conclusion: In high-risk settings, younger age, those with previous pneumonia hospitalisation, or ongoing respiratory symptoms/signs 4 weeks post-discharge from hospitalised CAP may be associated with incomplete CXR resolution. Consequently, follow-up imaging and monitoring may be warranted in these children.


  • Open Access

    Antibiotics for Paediatric Community-Acquired Pneumonia: What is the Optimal Course Duration?

    by Hing Cheong Kok, Anne B. Chang, Siew Moy Fong, Gabrielle B. McCallum, Stephanie T. Yerkovich, Keith Grimwood

    Despite significant global reductions in cases of pneumonia during the last 3 decades, pneumonia remains the leading cause of post-neonatal mortality in children aged <5 years. Beyond the immediate disease burden it imposes, pneumonia contributes to long-term morbidity, including lung function deficits and bronchiectasis. Viruses are the most common cause of childhood pneumonia, but bacteria also play a crucial role. However, the optimal duration of antibiotic therapy for bacterial pneumonia remains uncertain in both low- and middle-income countries and in high-income countries. Knowing the optimal duration of antibiotic therapy for pneumonia is crucial for effective antimicrobial stewardship. This is especially important as concerns mount over rising antibiotic resistance in respiratory bacterial pathogens, which increases the risk of treatment failure. Numerous studies have focused on the duration of oral antibiotics and short-term outcomes, such as clinical cure and mortality. In contrast, only one study has examined both intravenous and oral antibiotics and their impact on long-term respiratory outcomes following pneumonia hospitalisation. However, study findings may be influenced by their inclusion criteria when children unlikely to have bacterial pneumonia are included. Efforts to differentiate between bacterial and non-bacterial pneumonia continue, but a validated, accurate, and simple point-of-care diagnostic test remains elusive. Without certainty that a child has bacterial pneumonia, determining the optimal duration of antibiotic treatment is challenging. This review examines the evidence for the recommended duration of antibiotics for treating uncomplicated pneumonia in otherwise healthy children and concludes that the question of duration is unresolved.


  • Late Breaking Abstract - 24-month outcomes of extended vs standard-course antibiotic therapy in children hospitalised with pneumonia in high-risk settings: a multi-centre RCT

    by Hing Cheong Kok, Gabrielle Mccallum, Stephanie Yerkovich, Keith Grimwood, Siew Moy Fong, Anna Nathan, Catherine Byrnes, Robert Ware, Nachal Nachiappan, Noorazlina Saari, et al.

    Background: Community-acquired pneumonia (CAP) is associated with bronchiectasis. We determined if an extended (13-14 days) vs standard (5-6 days) antibiotic course improves long-term outcomes in children hospitalised with CAP from high-risk settings. Methods: We undertook a multi-centre RCT in Malaysian and Indigenous Australian and New Zealand children aged 3-months to ≤5-years hospitalised with CAP. They received 1-3 days of IV antibiotics, then 3-days of oral co-amoxiclav and were then randomised to extended (8-days oral co-amoxiclav) or standard-course (8-days oral placebo) arms. Children were reviewed at 12 and 24-months. The primary outcome was children with a composite endpoint of chronic respiratory symptoms/signs (chronic cough at 12 and 24-months; ≥1 subsequent hospitalised lower respiratory infection; or persistent/new chest x-ray signs at 12-months) at 24-months post-discharge. We used ITT analysis where children with incomplete follow-up were assumed to have chronic respiratory symptoms/signs. Results: 324 children were randomised (extended [n=163], standard [n=161]). For our primary outcome, chronic respiratory symptoms/signs occurred in 97/163 (60%) and 94/161 (58%) children in the extended and standard-courses respectively (RR 1.02, 95%CI 0.85-1.22). Where all sub-composite outcomes were known, chronic respiratory symptoms/signs occurred in 27/93 (29%) and 24/91 (26%) children from the extended and standard-courses respectively (RR 1.10, 95%CI 0.69-1.76). Conclusion: In children from high-risk populations hospitalised with CAP, 13-14 days of antibiotics (vs 5-6 days), did not improve long-term respiratory outcomes.

  • Twenty-four Month Outcomes of Extended- Versus Standard-course Antibiotic Therapy in Children Hospitalized With Pneumonia in High-risk Settings: A Randomized Controlled Trial

    by Hing C. Md Kok, Gabrielle B. BNursing McCallum, Stephanie T. Mbiostats Yerkovich, Keith MBChB Grimwood, Siew M. Mbbs Fong, Anna M. Mbbch Nathan, Catherine A. MBChB Byrnes, Robert S. Ware, Nachal Mbbs Nachiappan, Noorazlina Mbbs Saari, et al.

    Background: Pediatric community-acquired pneumonia (CAP) can lead to long-term respiratory sequelae, including bronchiectasis. We determined if an extended (13–14 days) versus standard (5–6 days) antibiotic course improves long-term outcomes in children hospitalized with CAP from populations at high risk of chronic respiratory disease. Methods: We undertook a multicenter, double-blind, superiority, randomized controlled trial involving 7 Australian, New Zealand, and Malaysian hospitals. Children aged 3 months to ≤5 years hospitalized with radiographic-confirmed CAP who received 1–3 days of intravenous antibiotics, then 3 days of oral amoxicillin-clavulanate, were randomized to either extended-course (8-day oral amoxicillin-clavulanate) or standard-course (8-day oral placebo) arms. Children were reviewed at 12 and 24 months. The primary outcome was children with the composite endpoint of chronic respiratory symptoms/signs (chronic cough at 12 and 24 months; ≥1 subsequent hospitalized acute lower respiratory infection by 24 months; or persistent and/or new chest radiographic signs at 12-months) at 24-months postdischarge, analyzed by intention-to-treat, where children with incomplete follow-up were assumed to have chronic respiratory symptoms/signs (“worst-case” scenario). Results: A total of 324 children were randomized [extended-course (n = 163), standard-course (n = 161)]. For our primary outcome, chronic respiratory symptoms/signs occurred in 97/163 (60%) and 94/161 (58%) children in the extended-courses and standard-courses, respectively [relative risk (RR) = 1.02, 95% confidence interval (CI): 0.85–1.22]. Among children where all sub-composite outcomes were known, chronic respiratory symptoms/signs between groups, RR = 1.10, 95% CI: 0.69–1.76 [extended-course = 27/93 (29%) and standard-course = 24/91 (26%)]. Additional sensitivity analyses also revealed no between-group differences. Conclusion: Among children from high-risk populations hospitalized with CAP, 13–14 days of antibiotics (versus 5–6 days), did not improve long-term respiratory outcomes.


  • Open Access

    Endotypes of Paediatric Cough—Do They Exist and Finding New Techniques to Improve Clinical Outcomes

    by Hannah E. O’farrell, Hing Cheong Kok, Suhani Goel, Anne B. Chang, Stephanie T. Yerkovich

    Chronic cough is a common symptom of many childhood lung conditions. Given the phenotypic heterogeneity of chronic cough, better characterization through endotyping is required to provide diagnostic certainty, precision therapies and to identify pathobiological mechanisms. This review summarizes recent endotype discoveries in airway diseases, particularly in relation to children, and describes the multi-omic approaches that are required to define endotypes. Potential biospecimens that may contribute to endotype and biomarker discoveries are also discussed. Identifying endotypes of chronic cough can likely provide personalized medicine and contribute to improved clinical outcomes for children.